Efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate
Arthritis Rheumatol. 2025 doi: 10.1002/art.43184 Epub ahead of print
Phase 2 study data show that zimlovisertib + tofacitinib was more effective than tofacitinib alone, in patients with moderate-to-severe RA and an inadequate response to MTX.
Danto, et al. help to address the unmet need for new treatment combinations strategies for patients who have failed targeted therapies, in this randomised, double-blind, five-arm, parallel-group, active comparator study conducted in patients with moderate-to-severe active RA across 77 centres in 10 countries. Their findings support the hypothesis that a combination of zimlovisertib and a JAK inhibitor theoretically has a broader anti-inflammatory profile that could improve clinical efficacy without an inferior safety profile.
